Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Maskell, Peter D.; Smith, Paul; Cole, Richard; Hikin, Laura; Morley, Stephen (2016)
Publisher: Elsevier
Languages: English
Types: Article
Subjects: Q1
Ethylphenidate is a stimulant novel psychoactive substance that is an analogue of the prescription drug methylphenidate (Ritalin®). Methylphenidate is used commonly for the treatment of attention deficit hyperactivity disorder. Due to its stimulant effects ethylphenidate is being abused. There is a single case report of a death associated with ethylphenidate in Germany, and a case series of 19 deaths in the East of Scotland, but otherwise, the contribution of ethylphenidate to death is poorly documented. We report the analytical results of 7 cases (between February 2013 and January 2015) in which ethylphenidate was detected and quantitated with a validated liquid chromatography tandem mass spectrometry method (LC-MS/MS). The individuals (all male) ranged in age from 23 to 49 years (median 25 years). The concentration of ethylphenidate in the cases ranged from 0.026mg/L to 2.18mg/L in unpreserved post-mortem femoral blood. Only one case had ethylphenidate present as a sole drug. All other cases had at least 2 other drug classes present (benzodiazepines, heroin, methadone antipsychotics, other new psychoactive compounds). Ethylphenidate toxicity was the sole contribution to the cause of death in one case. Hanging was the cause of death in 2 cases, with the other 4 cases being reported as having occurred due to mixed drug toxicity. These data will further help with the interpretation of post-mortem ethylphenidate levels.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • [1] Portoghese PS, Malspeis L. Relative hydrolytic rates of certain alkyl (b) dl-alpha-(2-piperidyl)- phenylacetates. J Pharm Sci. 1961;50:494-501.
    • [2] Zeitlin AL, Dariani MM. Phenidate drug formulations having diminished abuse potential. Google Patents; 2002.
    • [3] Spensley J, Rockwell DA. Psychosis during methylphenidate abuse. New England Journal of Medicine. 1972;286:880-1.
    • [4] EMCDDA. Annual Report: The State of the Drugs Problem in Europe. EMCDDA Lisbon; 2011.
    • [5] Office H. https://www.gov.uk/government/news/legal-highs-to-be-banned-under-temporarypower. 2015.
    • [6] Parks C, McKeown D, Torrance HJ. A review of ethylphenidate in deaths in east and west scotland. Forensic Science International. 2015.
    • [7] Bailey GP, Ho JH, Hudson S, Dines A, Archer Jr, Dargan PI, et al. Nopaine no gain: Recreational ethylphenidate toxicity. Clinical Toxicology. 2015:1-2.
    • [8] Ho JH, Bailey GP, Archer JR, Dargan PI, Wood DM. Ethylphenidate: availability, patterns of use, and acute effects of this novel psychoactive substance. European journal of clinical pharmacology. 2015;71:1185-96.
    • [9] Soussan C, Kjellgren A. “Chasing the High”-Experiences of Ethylphenidate as Described on International Internet Forums. Substance abuse: research and treatment. 2015;9:9.
    • [10] Stark M, Payne-James J, Scott-Ham M. Symptoms and signs of substance misuse: CRC Press; 2014.
    • [11] Pignon B, Muyssen A, Deheul S, Cottencin O, Rolland B. Dependence on Internet-purchased ethylphenidate. Journal of clinical psychopharmacology. 2015;35:472-3.
    • [12] Koehm M, Kauert GF, Toennes SW. Influence of ethanol on the pharmacokinetics of methylphenidate's metabolites ritalinic acid and ethylphenidate. Arzneimittel-Forschung. 2009;60:238-44.
    • [13] Patrick K, Straughn A, Minhinnett R, Yeatts S, Herrin A, DeVane C, et al. Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clinical Pharmacology & Therapeutics. 2007;81:346-53.
    • [14] Markowitz JS, DeVane CL, Boulton DW, Nahas Z, Risch SC, Diamond F, et al. Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol. Drug Metabolism and Disposition. 2000;28:620-4.
    • [15] Uges D. Hospital toxicology. Clarke's Analysis of Drugs and Poisons in Pharmaceuticals, Body Fluids and Postmortem Material, 3rd Ed Pharmaceutical Press, London, UK. 2004:3-36.
    • [16] Peters FT, Drummer OH, Musshoff F. Validation of new methods. Forensic science international. 2007;165:216-24.
    • [17] Matuszewski B, Constanzer M, Chavez-Eng C. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical chemistry. 2003;75:3019-30.
    • [18] Krueger J, Sachs H, Musshoff F, Dame T, Schaeper J, Schwerer M, et al. First detection of ethylphenidate in human fatalities after ethylphenidate intake. Forensic science international. 2014;243:126-9.
    • [19] Martinez-Raga J, Knecht C, Szerman N, Martinez MI. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. CNS drugs. 2013;27:15-30.
    • [20] Lin SN, Andrenyak DM, Moody DE, Foltz RL. Enantioselective gas chromatography-negative ion chemical ionization mass spectrometry for methylphenidate in human plasma. J Anal Toxicol. 1999;23:524-30.
    • [21] Nakajima K, Kotaki H, Saitoh Y, Nakagawa F. Determination of methylphenidate and its main metabolite in plasma by gas chromatography-chemical ionization mass spectrometry. Chemical and Pharmaceutical Bulletin. 1986;34:1701-8.
  • No related research data.
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Cite this article